Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
In order to deliver the Contracting Authorities advanced therapies experimental medicine programme there is a requirement for construction of a new adeno-associated virus (AAV) viral vector GMP manufacturing unit and a new cell therapy unit to allow the manufacture of additional and broader range of cell therapy products, including embryonic stem cell derived products.
No supplier information available.